West Pharmaceutical Services appointed Michel Lagarde as President and Chief Executive Officer effective August 31, 2026, marking a leadership transition at the Pennsylvania-based injectable drug delivery specialist. Lagarde, who departs Thermo Fisher Scientific where he served as Executive Vice President and Chief Operating Officer, will succeed Eric Green, who announced his planned retirement in March after 11 years leading the company. Lead Independent Director Robert Friel will assume the Board Chair position on the same date, separating the roles previously held by Green.
The Board engaged a leading executive recruiting firm to conduct the search, completing the process in roughly four months. Friel praised Lagarde as possessing "the precise blend of visionary insight, customer-centric mindset, and exceptional leadership skills" needed to lead West into its next growth phase. Lagarde highlighted the strategic rationale for his move, noting that "the life sciences industry is at a pivotal point" where "the demand for reliable, high-quality delivery of injectable medicines has never been greater." Green, during whose tenure West more than doubled sales and generated approximately 350% total shareholder return, remains supportive of the succession plan.
Lagarde brings extensive pharma services experience across multiple executive roles spanning manufacturing, private equity and large-cap operations. He spent nine years at Thermo Fisher in increasingly senior positions, including a 2019 promotion to EVP with responsibility for Pharma Services, Customer Channels and other major business units. Before that, he served as President and COO of Patheon from 2016 to 2017, and spent eight years at JLL Partners as Managing Director overseeing healthcare portfolio companies including Patheon, where he helped transform operations into a global biopharma development and manufacturing provider. Earlier in his career, he held finance and operational leadership roles at Philips Electronics across multiple geographies, including a $1 billion industrial footprint in Hong Kong. Lagarde also serves as Chair of the Audit and Finance Committee at Vertex Pharmaceuticals, a position he has held since joining the board in 2023.
West Pharmaceutical operates 50 sites including 26 manufacturing facilities worldwide and delivered over 41 billion components and devices in fiscal 2025, generating $3.07 billion in net sales. The company dominates the injectable drug delivery ecosystem, commanding approximately 70 percent of the global elastomeric components market for injectable packaging. West benefits from secular growth in biologic drugs and specialised injectable therapies, particularly the surging demand from GLP-1 obesity and diabetes treatments. The company is included in the S&P 500 index and carries a market capitalisation of approximately $22.3 billion.
Lagarde's appointment suggests the Board sought to strengthen operational rigour and pharma manufacturing expertise to navigate accelerating innovation in injectable delivery. His track record at Thermo Fisher demonstrates facility with large-scale operational transformation, while his tenure at Patheon signals comfort managing high-growth, capital-intensive contract manufacturing operations. The timing is significant: Lagarde exits Thermo Fisher just months after the company announced his departure in January 2026 to pursue other opportunities, indicating the West role was secured well in advance. By contrast, Green's 350 percent shareholder return established exceptionally high expectations. Whether Lagarde can sustain West's margin profile and growth trajectory amid competitive pressures and potential customer insourcing risk will likely define market perception of this succession.
